secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001810182-25-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology: CMO Alan Sandler resigns, Barbara Klencke appointed Interim CMO; Nasdaq compliance regained
--------------------------------------------------------------------------------

- Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.
- Barbara Klencke steps down from Board to become Interim CMO effective Sep 17, 2025.
- ALX regained Nasdaq minimum bid price compliance (closing bid >= $1 for 10 consecutive days through Sep 4, 2025).
- Board committee changes: R&D committee paused; new Audit, Compensation, and Governance committee assignments approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/0001810182-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/alxo-20250911.htm
  HTML page:      https://secwatch.observer/filing/0001810182-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer